SOM Biotech Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
SOM Biotech General Information
Description
Developer of drugs designed for the treatment of rare and critical diseases. The company's artificial intelligence-based drug discovery technology allows for reducing costs and time in drug development, provide a high level of success and reliable patent protection, and engaging in the development of candidates, drug pipelines, and compounds to treat diseases, enabling the medical community to optimally combat acute and life-threatening diseases while maintaining safety and tolerance standards.
Contact Information
Website
www.sombiotech.comCorporate Office
- Carrer de Baldiri Reixac, 4
- 08028 Barcelona
- Spain
Corporate Office
- Carrer de Baldiri Reixac, 4
- 08028 Barcelona
- Spain
SOM Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Secondary Transaction - Private | Completed | Clinical Trials - Phase 3 | ||||
| 10. Later Stage VC (Series B) | 03-Nov-2023 | Completed | Clinical Trials - Phase 3 | |||
| 9. Later Stage VC (Series A) | 01-Jan-2021 | Completed | Clinical Trials - Phase 3 | |||
| 8. Later Stage VC | 08-Mar-2019 | Completed | Clinical Trials - Phase 3 | |||
| 7. Later Stage VC | 01-Jul-2017 | Completed | Clinical Trials - Phase 3 | |||
| 6. Product Crowdfunding | 02-Feb-2016 | Completed | Startup | |||
| 5. Later Stage VC | 07-Aug-2015 | Completed | Startup | |||
| 4. Grant | 10-Oct-2013 | Completed | Startup | |||
| 3. Grant | 30-Oct-2012 | $389K | $992K | Completed | Startup | |
| 2. Grant | 13-Sep-2012 | $528K | $992K | Completed | Startup |
SOM Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | 101,648 | $0.011326 | $8.56 | $8.56 | 1x | $8.56 | 0.19% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
SOM Biotech Comparisons
Industry
Financing
Details
SOM Biotech Competitors (4)
One of SOM Biotech’s 4 competitors is Healx, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Healx | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| BenevolentAI | Formerly PE-Backed | Luxembourg, Luxembourg | ||||
| Recursion Pharmaceuticals | Formerly VC-backed | Salt Lake City, UT |
SOM Biotech Patents
SOM Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026175555-A1 | Pharmaceutical composition comprising bevantolol for the treatment of mental disorders | Pending | 18-Feb-2025 | ||
| AU-2023222467-A1 | Compounds for use in the treatment of dystrophinopathies | Pending | 21-Feb-2022 | ||
| EP-4230196-A1 | Compounds for use in the treatment of dystrophinopathies | Inactive | 21-Feb-2022 | ||
| EP-4482481-A1 | Compounds for use in the treatment of dystrophinopathies | Active | 21-Feb-2022 | ||
| EP-4482481-B1 | Compounds for use in the treatment of dystrophinopathies | Active | 21-Feb-2022 | A61K31/4402 |
SOM Biotech Signals
SOM Biotech Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Prevail Partners | Venture Capital | Minority | ||
| Additio Investment Group | Venture Capital | Minority | ||
| Convergence Partners (Switzerland) | Venture Capital | Minority | ||
| Health Technology Holding | Venture Capital | Minority | ||
| Monte Carlo Capital | Venture Capital | Minority |
SOM Biotech FAQs
-
When was SOM Biotech founded?
SOM Biotech was founded in 2009.
-
Where is SOM Biotech headquartered?
SOM Biotech is headquartered in Barcelona, Spain.
-
What is the size of SOM Biotech?
SOM Biotech has 15 total employees.
-
What industry is SOM Biotech in?
SOM Biotech’s primary industry is Drug Discovery.
-
Is SOM Biotech a private or public company?
SOM Biotech is a Private company.
-
What is SOM Biotech’s current revenue?
The current revenue for SOM Biotech is .
-
How much funding has SOM Biotech raised over time?
SOM Biotech has raised $48.1M.
-
Who are SOM Biotech’s investors?
Prevail Partners, Additio Investment Group, Convergence Partners (Switzerland), Health Technology Holding, and Monte Carlo Capital are 5 of 7 investors who have invested in SOM Biotech.
-
Who are SOM Biotech’s competitors?
Healx, Exscientia, BenevolentAI, and Recursion Pharmaceuticals are competitors of SOM Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process